Lupin Licenses US Rights for Proprietary Bioadhesive Technology for Rifaximin to Salix Pharmaceuticals
Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.
Lupin and Salix have entered into an agreement under which the two companies will collaborate in the development and commercialization of an extended release product incorporating Rifaximin and utilizing Lupin's proprietary bioadhesive technology. In connection with this agreement, Lupin and Salix have also entered into an exclusive agreement in the United States for supply of Rifaximin active pharmaceutical ingredient (API). Salix has made a $5 million up-front payment and will make additional regulatory milestone payments to Lupin. In addition, Salix will pay royalties on net sales of the bioadhesive Rifaximin product to Lupin.
Comments